Giuseppe Benagiano

Giuseppe Benagiano

Auto-generated profile, based on publicly available information

Giuseppe Benagiano

Unicamillus. Saint Camillus International University of Health and Medicine

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2017 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
MFManuela Farris
Manuela Farris
CBCarlo Bastianelli
Carlo Bastianelli
ERElena Rosato
Elena Rosato
IBIvo Brosens
Ivo Brosens
GBGiuseppe Benagiano
Giuseppe Benagiano
Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations. Special emphasis is given to products containing natural estrogens. Areas covered: Recent information on the effect of androgens, estrogens, progestins, as well as various COC combinations on the coagulation cascade will be reviewed aiming at providing an updated picture. The present article reviews hemostatic changes occurring during use of classic and modern combinations of estrogens (ethinyl estradiol, estradiol, estradiol valerate and estetrol) and new progestins (desogestrel, gestodene, dienogest, drospirenone, nomegestrol acetate), compared to classic compounds, such as levonorgestrel. Both pro- and anti-coagulatory effects of COC in healthy women are detailed and possible links with incidence of thromboembolic events are discussed. Expert commentary: Overall, the picture is reassuring: the use of natural estrogens and of new generation progestins has reduced pro-coagulatory changes in healthy subjects, although the observed differences in the risk of venous thromboembolism between second and third generation progestins is still incompletely understood. At the same time, there still is a need for large comparative and surveillance studies before firm conclusions can be drawn. At any rate, available evidence indicates that hemostatic effects of the newer COC, especially those utilizing natural estrogens, are minimal and often remain with the normal range.

21 September 2020 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
CBCarlo Bastianelli
Carlo Bastianelli
MFManuela Farris
Manuela Farris
VBVincenzina Bruni
Vincenzina Bruni
ERElena Rosato
Elena Rosato
IBIvo Brosens
Ivo Brosens
GBGiuseppe Benagiano
Giuseppe Benagiano
The contraceptive activity of synthetic progestins is mediated through three basic mechanisms: (a) An anti-gonadotrophic action leading to the inhibition of ovulation; (b) Changes in cervical mucus...

13 February 2020 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
CBCarlo Bastianelli
Carlo Bastianelli
MFManuela Farris
Manuela Farris
VBV. Bruni
V. Bruni
IBIvo Brosens
Ivo Brosens
GBGiuseppe Benagiano
Giuseppe Benagiano
Introduction: Steroid hormones are responsible for specific changes in the endometrium during the menstrual cycle, when they are sequentially secreted and, because of this, in the early days sequential combined oral contraceptive regimens were utilized. The same basic concept has been utilized with multi-phasic regimens, in order to produce endometrial pictures mimicking the normal cycle. Areas covered: The Endometrial effects of: progestins and estrogens; combined monophasic high- (50μg), medium- (30μg), low- (20μg), ultralow- (15μg) estrogen content; sequential regimens; multiphasic combinations; treatment schedules. Cervical effects of combined high-dose and sequential combinations, including evidence for an increase in malignant lesions. Expert commentary: Overall, combined oral contraceptives (COCs) inhibit normal proliferative changes and the endometrium becomes thin, narrow, with widely spaced glands and pre-decidual changes in the stroma. During the first few cycles the progestin induces a coexistence of proliferative and secretory features; with time, the picture changes because the progestin induces a down-regulation of estrogen receptors, resulting in tortuous glands similar to those in the secretory phase, but characterized by a quiescent, atrophic glandular epithelium. In the cervical epithelium, under the influence of high-dose COCs, endocervical glands became hypersecretory and in some instances, distinctive type of atypical polypoid endocervical hyperplasia, is found.

3 June 2025 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
MFManuela Farris
Manuela Farris
CBCarlo Bastianelli
Carlo Bastianelli
MHMarwan Habiba
Marwan Habiba
GBGiuseppe Benagiano
Giuseppe Benagiano
Pincus and his group's initial research on hormonal contraception focused on progesterone. However, the natural compound could not be utilized in clinical practice because of the high incidence of breakthrough bleeding and its low oral availability. This led to the introduction of orally active progestins. The estrogen was added to ensure proper cycle control. Concern about side effects of combined oral contraceptive pills (COC) and specifically the increased occurrence of thromboembolism was raised at the very early stages of clinical use. These were attributed to the estrogenic component, ethinyl estradiol (EE). The first pill scare followed the publication in 1977 of evidence of thromboembolism-related mortality in COC users. This and subsequent alarming publications acted as the engine for a successful attempt to substantially decrease the daily content of EE in a COC. Over time, adverse events were also reported for the newer progestins compared to levonorgestrel. Attempts have been made to utilize natural estrogens in COC based on the assumption that this will reduce adverse effects. The wide range of progestins available for use in COC renders comparisons between preparations more challenging. Each progestin has its own androgenic, antiandrogenic, antiestrogenic, and mineralocorticoid activity and, consequently, a unique risk and benefit profile.

3 June 2025 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
MFManuela Farris
Manuela Farris
CBCarlo Bastianelli
Carlo Bastianelli
MHMarwan Habiba
Marwan Habiba
GBGiuseppe Benagiano
Giuseppe Benagiano
Marketing in the late 1950s of Combined Oral Contraceptives (COC) represented the achievement of centuries of research in reproductive endocrinology that included the isolation of the main steroids produced, within the concept of 'internal secretion,' by the ovaries and corpus luteum. Key observations made at the end of the 19th century proved that the presence of corpus luteum induces temporary infertility in animals and that ovaries secrete hormonally active substances. During the 1930s, the four main hormones (progesterone, estrone, estradiol, and estriol) were identified and their structure determined. The recognition that natural compounds are not effective when given orally, stimulated the search for synthetic steroids. Ethinyl-estradiol, synthesized in 1937, remains even today the most widely used estrogenic component of COC, although other compounds (micronized estradiol, estradiol valerate, estetrol) have been incorporated in COC. A variety of synthetic progestins have become available since the early 1950s having different progestogenic potency, pharmacokinetic and pharmacodynamic properties. Started with observations made three centuries ago, development of COC has gone beyond the dream of the early investigators: literally dozens of formulations are available today capable of satisfying the needs of the majority of women of fertile age and the work continues.

1 July 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
IBIvo Brosens
Ivo Brosens
GBGiuseppe Benagiano
Giuseppe Benagiano